MorphoSys AG (Nasdaq: MOR) MorphoSys is down 29.01% premarket after partner Roche says its Alzheimer's drug trials didn't meet its goals. The experimental medicine, galled gantenerumab, didn't slow clinical decline in people with early Alzheimer's, the Swiss drugmaker said Monday. Overall, the medicine didn't match the success of Biogen Inc. and Eisai Co's lecanemab, as it removed less beta amyloid protein than researchers had expected in patient's brains. Medical innovations don't always come to fruition, but when they do, there can be massive gains to be made. See why our friend Alexander Green is so high on this one medical device that's been called 'humanity's next big leap.' Elon Musk recently sent this device into orbit and right now you can get in for just $3. Click here to discover this game-changing medical stock. Dentsply Sirona Inc. (Nasdaq: XRAY) Dentsply is down 10.76% premarket after the company suffered a $1.08 billion net loss in the third quarter of 2022. The dental products maker cut its full-year outlook, citing weaker demand, supply chain challenges and unfavorable currency translation. As more and more companies suffer losses in 2022, it's crucial to look at other ways to invest outside of the stock market. See why one of the world's most popular 'inflation-proof' assets could be banned in America soon, and why you should move your money by December 14, 2022. Click here to learn how to protect your assets. Those are the top market movers today. Happy trading! The Wake-Up Watchlist Research Team |
Post a Comment
Post a Comment